Dipeptidyl-peptidase III (DPP III) is a cytosolic metallo-aminopeptidase implicated in various physiological and pathological processes. A previous study from our laboratory indicated an elevated expression of DPP III in glioblastoma (U87MG) cells. In the present study we investigated the role of interleukin-6 (IL-6), a pleiotropic cytokine produced by glial tumors, in the regulation of DPP III expression. Immunohistochemistry, western blotting and quantitative RT-PCR were used for quantitation of DPP III and IL-6 in human glioblastoma cells and tumors. Cell transfections and DPP III promoter reporter assays were performed to study the transcriptional regulation of DPP III by IL-6. Promoter deletion analysis, site directed mutagenesis, chromatin immunoprecipitation assays and small interfering RNA (siRNA) technology was employed to elucidate the molecular mechanism of IL-6 mediated regulation of DPP III expression in glioblastoma cells. Our results for the first time demonstrate a negative correlation (r =0.632, P =0.01) between DPP III and IL-6 in both human tumors and cultured glioblastoma cells. Treatment of U87MG cells with IL-6 significantly decreased DPP III expression with a concomitant increase in the levels of transcription factor CCAAT/enhancer binding protein beta (C/EBP-β). Deletion/mutagenesis of C/EBP-β binding motif of DPP III promoter significantly increased its activity and abolished its responsiveness to IL-6. This effect could also be mimicked by C/EBP-β siRNA. In conclusion our study for the first time demonstrates C/EBP-β mediated transcriptional downregulation of DPP III by IL-6. Our results demonstrating a negative correlation between IL-6 and DPP III taken together with the previously reported prognostic significance of this cytokine in glioblastoma suggests that DPP III may prove useful as a prognostic marker.
Interleukin-6 (IL-6), a pleiotropic cytokine, regulates diverse processes such as cell proliferation and survival, neuronal differentiation, inflammation, bone metabolism, hematopoiesis and nociception [1-6]. It has also been demonstrated to promote the growth of several human tumors including glioblastoma [7-10]. The expression of this cytokine is often elevated in glial tumors and plays an important role in malignant progression by facilitating tumor angiogenesis and invasion [11, 12]. Chang et al.  observed variable expression of IL-6 in glioblastoma multiforme and linked its elevated expression with poor prognosis of the disease.
Dipeptidyl-peptidase III (DPP III), a cytosolic aminopeptidase implicated in a number of physiological and pathological processes, is ubiquitously expressed in human tissues . A strong positive correlation has been reported between DPP III and ovarian cancer and its activity increases with increase in the histological aggressiveness of the disease . In a previous study the highest DPP III promoter activity was observed in glioblastoma cells as compared to other cell lines thereby indicating its elevated expression in these cells . Glioblastoma cells also produce IL-6 in vivo as well as in vitro and its elevated levels of expression distinguish glioblastoma from low grade astrocytoma . Our laboratory previously cloned DPP III promoter and demonstrated a critical role of Ets-1/Elk-1 in transcription of this peptidase in U87MG cells . The present study was planned to investigate the role of IL-6 in regulation of DPP III expression and to elucidate its molecular mechanism. Our results for the first time demonstrate transcriptional downregulation of DPP III expression by IL-6 and conclusively establish the role of CCAAT/enhancer binding protein beta (C/EBP-β) in this process.
Expression of DPP III and IL-6 in human glioblastoma cells
IL-6 is a pleiotropic cytokine which alters the expression of a variety of proteins in glioblastoma cells. Since previous studies from our laboratory indicated an elevated expression of DPP III in human glioblastoma (U87MG) cells  it was of interest to study the role of IL-6 (if any) in regulating the expression of this peptidase. In order to investigate if any correlation exists between the two we assessed the expression of DPP III and IL-6 in several human glioblastoma cells (LN229, LN18, U373MG and U87MG) by western blotting and the results are shown in Fig. 1. These results revealed detectable levels of DPP III and IL-6 expression in all human glioblastoma cells. However, the levels varied between different cell lines. Of all the cell lines studied U87MG cells express the highest levels of DPP III followed by U373MG cells, LN229 and LN18 (Fig. 1). Interestingly the levels of IL-6 were found to be maximum in LN18 followed by LN229, U373MG and U87MG. Densitometry of the specific bands followed by normalization with the levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) revealed an inverse relationship between the expression of DPP III and IL-6 (Fig. 1B). Spearman's correlation analysis revealed a significant negative correlation (r =0.832; P ≤0.05) between the two. To further corroborate these results, expression of DPP III and IL-6 was assessed by immunohistochemistry in glioblastoma stage IV tumors (n =25). As shown in Fig. 2, consistent with our findings in various glioblastoma cells, variable expression of DPP III and IL-6 found in glial tumors exhibited a significant negative correlation (r =0.632; P =0.01).
IL-6 treatment decreases DPP III expression in U87MG cells
The results presented in the preceding section established a negative correlation between IL-6 and DPP III expression in glioblastoma cells and tumors. In an attempt to elucidate whether elevated levels of IL-6 are indeed responsible for downregulation of DPP III expression, U87MG glioblastoma cells were treated with 100 nm of recombinant IL-6. After 24 h of this treatment the expression of DPP III in IL-6 treated and untreated cells was assessed by western blotting and real-time PCR. As evident from Fig. 3, IL-6 treatment significantly decreased DPP III expression. Similarly a parallel decrease was observed in its mRNA levels (Fig. 3C). These results conclusively demonstrate the direct involvement of IL-6 in decreasing DPP III levels and suggest that this decrease may be due to either its transcriptional downregulation or decrease in its mRNA stability.
Transcriptional downregulation of DPP III expression by IL-6
Shukla et al. cloned and characterized human DPP III promoter. We used human full-length (−1033⁄+ 5 bp) DPP III promoter reporter construct (pAAS-1) to assess the role of transcription in IL-6 mediated reduction of DPP III levels . For this purpose the luciferase activity in U87MG cells transiently transfected with pAAS-1 was assayed after treatment with 100 nm IL-6 or vehicle solution. As shown in Fig. 4, significantly less DPP III promoter activity (P =0.047) was detected in IL-6 treated cells compared with untreated cells. No such effect was observed on SV-40 promoter suggesting the specific effect of IL-6 on DPP III promoter. Furthermore these results demonstrated the role of transcription in downregulation of DPP III expression by IL-6 in U87MG cells.
Identification of IL-6 response element(s) in DPP III promoter
Shukla et al. performed 5′ deletion analysis to characterize DPP III promoter and generated several promoter reporter constructs. Some of these constructs (pASS-1, pAAS-2 and pASS-3) were used in the present study for the identification of IL-6 response element(s). As shown in Fig. 5, deletion of the promoter region between 1033 and 781 did not have any effect on promoter activity or responsiveness to IL-6 treatment. However, further deletion of the promoter region up to −495 (pRS-1) significantly reduced promoter activity but retained responsiveness to IL-6. Interestingly, deletions of 10 bp from the 5′ end of pRS-1 led to a dramatic increase in promoter activity with a concomitant loss of responsiveness to IL-6 (Fig. 5). These results suggested that the above mentioned 10 bp region contains potential negative regulatory and IL-6 response element(s). Nucleotide sequence analysis of DPP III promoter by an online tool transfac 6.0 revealed the presence of a single C/EBP-β binding motif (5′ GCTTTGCAAC 3′) spanning between nucleotides −487 and −478 and an NF-1 binding motif between −476 and −467 nucleotides (Fig. 6). Since 5′ deletion of the promoter region up to −485 bp resulted in the deletion of nucleotides AG which were part of only the C/EBP-β binding motif and not that of NF-1 motif, the possibility of later being part of the IL-6 response element was ruled out. To further confirm this hypothesis we specifically mutated C/EBP-β binding motif by site directed mutagenesis in the full-length promoter reporter construct pAAS-1. This mutagenesis led to a significant increase in promoter activity and abolished its responsiveness to IL-6 (Fig. 7). From these results we concluded that C/EBP-β binding motif functions as a negative regulatory element and it alone was sufficient for conferring responsiveness to IL-6.
Binding of C/EBP-β to its cognate motif on DPP III promoter
Chromatin immunoprecipitation (ChIP) assays were performed to assess the in vivo binding of C/EBP-β to its cognate motifs on DPP III promoter. For these assays chromatin from U87MG cells was immunoprecipitated using C/EBP-β antibody and subjected to semiquantitative PCR using specific primers designed on the basis of the nucleotide sequence flanking the C/EBP-β binding motif on DPP III promoter. Analysis of the PCR products revealed the amplification of the expected size DNA fragment (196 bp) when chromatin immunoprecipitated with C/EBP-β antibody or input chromatin was used as template respectively (Fig. 8). These amplified fragments were subjected to double-stranded DNA sequencing and the nucleotide sequence thus obtained exhibited complete homology to the DPP III promoter region expected to be amplified (data not shown). However, when chromatin immunoprecipitated using the total rabbit anti-mouse IgG was used as template no such amplification by PCR was evident (Fig. 8, lane 6). Interestingly, when PCR was performed using C/EBP-β antibody immunoprecipitated chromatin from IL-6 treated cells as template we observed a perceptible increase in the intensity of the amplified band (Fig. 8, lane 3) compared with when similar chromatin of the untreated cell was used as template (Fig. 8, lane 5).
Silencing of C/EBP-β increases DPP III expression and its promoter activity
The results of the preceding section clearly demonstrated increased binding of C/EBP-β to its cognate motif on DPP III promoter in response to IL-6 treatment in U87MG cells. However, it was not clear whether IL-6 treatment induces C/EBP-β expression or facilitates the binding of existing C/EBP-β to its motif. Similarly there was no information about whether an increase in C/EBP-β levels alone was sufficient to downregulate DPP III expression in response to IL-6. In the present study we assessed the expression of C/EBP-β in IL-6 treated U87MG cells and employed small interfering RNA (siRNA) mediated silencing of C/EBP-β to address these questions. As is evident from Fig. 9, treatment of U87MG cells with 100 nm of IL-6 resulted in a statistically significant increase (P ≤0.05) in C/EBP-β expression with a concomitant decrease in DPP III levels (P ≤0.05) while the expression of GAPDH remained unaltered.
We constructed three C/EBP-β siRNA expression vectors (shC/EBP-β 259, shC/EBP-β 269 and shC/EBP-β 1417) to silence C/EBP-β expression and a scrambled siRNA vector (shSc). The details of the construction of these vectors are given in 'IL-6 treatment decreases DPP III expression in U87MG cells' and nucleotide sequences are given in Table 1. These vectors were independently transfected into U87MG cells and the expressions of C/EBP-β, DPP III and GAPDH were assessed 48 h post transfection by western blotting. The results are presented in Fig. 10. As shown in Fig. 10A,B, transfection of U87MG cells with shC/EBP-β 259 or shC/EBP-β 1417 led to a statistically significant decrease in the levels of C/EBP-β with a parallel and significant increase in DPP III expression compared with mock transfected cells. However, neither the expression of C/EBP-β nor that of DPP III was altered in these cells after the transfection of shC/EBP-β 269 or shSc. Similarly the expression of GAPDH was not affected by C/EBP-β siRNA confirming its specificity against C/EBP-β alone.
Table 1. Oligonucleotides used for various experiments in the present study.
Nucleotide sequence (5′→3′)
For real time PCR
DPP III F-20 (sense)
Amplicon size 155 bp
Amplicon size 173 bp
For promoter deletion analysis
DPP III F 495
Contains XhoI site
DPP III NR (antisense)
Contains HindIII site
For site directed mutagenesis of C/EBP-β motif
DPP III F2 (sense)
Contains XhoI site
DPP III C/EBP-β Mut F (sense)
Mutated bases are in lower case
DPP III C/EBP-β Mut R (antisense)
Mutated bases are in lower case
DPP III NR (antisense)
Contains HindIII site
For ChIP assays
Amplicon size 195 bp
For construction of C/EBP-β siRNA and scrambled siRNA expression vectors
ApaI and EcoRI adaptor sequences are shown in bold
To further corroborate our findings we co-transfected the above mentioned siRNA expression vectors with DPP III promoter reporter construct pAAS-1 in U87MG cells followed by assaying luciferase activity. Consistent with the above results shC/EBP-β 259 or shC/EBP-β 1417 which silenced the expression of C/EBP-β led to a significant (P ≤0.05) increase in DPP III promoter activity compared with shSc (Fig. 10C) whereas shC/EBP-β 269 did not have any effect on promoter activity. These findings convincingly establish that IL-6 treatment increases C/EBP-β levels which alone is sufficient for transcriptional downregulation of DPP III expression.
Glioblastoma cells produce IL-6 in vitro and in vivo, which in turn promotes their proliferation and invasive ability and inhibits apoptosis [11, 12, 17, 18]. Some of these effects are mediated by the induced expression of STAT-3, VEGF, MMP-2 and facin-1 etc. [11, 19, 20]. Li et al. demonstrated that IL-6 augments the invasiveness of U87MG cells by upregulation of MMP-2 and fascin-1 expression . Similarly, increased expression of a number of other endopeptidases (proteinases) and exopeptidases confers invasive ability to these tumor cells [21-23]. The expression of metallo-aminopeptidase DPP III also increases with increase in the histological aggressiveness of human ovarian carcinoma . We have previously observed that of all the cell lines studied U87MG cells displayed highest DPP III promoter activity thereby indicating its highest expression in these cells . Interestingly, the results of the present study for the first time demonstrate a wide variation in the expression of this peptidase in human glioblastoma and even in various cell lines derived from it. The levels of DPP III mRNA and protein exhibit an inverse correlation with that of IL-6. Of all the glioblastoma cells used in the present study we observed lowest expression of IL-6 in U87MG cells. As these cells harbor wild type p53 (Wtp53) our findings are consistent with those of Margulies and Sehgal who observed repression of IL-6 promoter by Wtp53 . However, we did not observe any correlation between the levels of IL-6 and p53 status in other lines (LN18, LN229 and U373MG). Treatment of U87MG cells with IL-6 led to a significant (P ≤0.05) decrease in the levels of DPP III mRNA and protein, thereby establishing a direct role of IL-6 in downregulation of DPP III expression. IL-6 has also been demonstrated to downregulate the expression of aldolase B, albumin, fibronectin, transferrin, PXR (pregnane X receptor), CAR (constitutively activated receptor) and human type II collagen genes [25-29].
Our laboratory previously cloned human DPP III promoter and established the critical role of Ets-1/Elk-1 in the transcription of this peptidase in human glioblastoma cells. In the present study we observed a statistically significant decrease in DPP III promoter activity by IL-6 treatment. C/EBP-β can function as a transcriptional activator as well as repressor [30-38]. By deletion analysis and ChIP assays we identified a single functional C/EBP-β binding motif in the IL-6 response region of DPP III promoter whose mutagenesis completely abolished its responsiveness to IL-6. Thus, our results are in agreement with the reports where C/EBP-β has been shown to downregulate the expression of albumin and CD200R1 [33, 37]. IL-6 treatment increased the expression of C/EBP-β in human astrocytoma, glioblastoma, hepatocellular carcinoma, renal cell carcinoma and breast cancer cells [39-43]. We observed elevated expression and binding of C/EBP-β to its cognate motif on DPP III promoter in response to IL-6 treatment. Aigueperse et al.  demonstrated the involvement of NF-1 and Sp-1 along with C/EBP-β in regulation of mouse aldose reductase like gene expression. DPP III promoter contains NF-1 (−476 to −467) and Sp-1(−468 to −459) binding motifs in close vicinity to the C/EBP-β motif. However, mutagenesis of these two binding sites did not have any effect on reduction of promoter activity by IL-6 (data not shown). So it was inferred that the C/EBP-β motif alone was sufficient to confer IL-6 responsiveness to the DPP III promoter. Our laboratory has previously demonstrated the role of C/EBP-α in acetaldehyde mediated downregulation of human cathepsin L in hepatocytes by silencing of C/EBP-α expression . In the present study also we designed an siRNA expression vector for silencing C/EBP-β expression and our results demonstrate that expression vectors which reduce C/EBP-β expression induce DPP III promoter activity and expression without having any effect on GAPDH levels. From these results we conclude that downregulation of DPP III expression by IL-6 is mediated by C/EBP-β and alteration in the level of this transcription factor alone is sufficient for this effect.
Endogenous opioid peptide synthesized and secreted by the central nervous system produces diverse effects including relief from pain. Bezerra et al. demonstrated entropy driven binding of opioid peptides (endomorphin-1 and leu-enkephalin) to DPP III and proposed them to be the natural substrate of this peptidase . Consistent with this report Barsun et al. reported cleavage of endomorphins by human DPP III . Thus increased activity/levels of this peptidase may be expected to result in decreased concentration of these analgesic peptides thereby increasing the perception of pain. Downregulating the expression of this opioid cleaving peptidase may be a conceivable physiological response to minimize pain. Sato et al. indeed observed a significant reduction in DPP III activity in the cerebrospinal fluid of patients with acute pain thereby again suggesting its involvement in pain modulation . The majority of glioblastoma patients experience pain due to increased intracranial pressure exerted by the large tumor volume. Our results demonstrating reduction of DPP III in glioblastoma by IL-6 may thus be a patient's physiological response to minimize the pain associated with the aggressive form of glioblastoma. Elevated expression of IL-6 exhibits a strong correlation with a very aggressive form of glioblastoma and shortened survival of the patients [11-13, 48]. The results of the present study for the first time demonstrate a strong negative correlation between IL-6 and DPP III expression in glioblastoma tumors and cultured cells. Our results in view of the known prognostic significance of IL-6 suggest an association between decreased DPP III level and poor outcome in glioblastoma patients.
Materials and methods
Human glioblastoma cells U87MG, U373MG, LN18 or LN229 obtained from the National Centre for Cell Science, Pune, India, were grown in Dulbecco's modified Eagle's medium (Gibco Life Technologies, Karlsruhe, Germany) containing high glucose (4.5 g·L−1) and supplemented with 20 μg·mL−1 ciprofloxacin and 10% fetal bovine serum (Gibco Life Technologies) in a humidified atmosphere containing 5% CO2 at 37 °C. The cells were subcultured or harvested for analysis after they achieved 75–80% confluence.
Antibodies against human C/EBP-β and GAPDH were purchased from Abcam (Cambridge, UK), DPP III from Thermo Fisher Scientific Inc. (Rockford, IL, USA) and IL-6 from Santa Cruz Inc. (Dallas, TX, USA).
Tumor and biopsy specimens
Histologically confirmed grade IV archival glioblastoma tissue samples (n =25) were included in the present study after obtaining formal approval from the Institutional Human Ethics Committee of the All India Institute of Medical Sciences, New Delhi, India.
Paraffin-embedded sections (5 μm) of grade IV human glioblastoma (n =25) were collected on gelatin-coated slides, deparaffinized in xylene, hydrated in descending grades of alcohol, and pretreated in a microwave oven for 15 min in citrate buffer (0.01 m, pH 6.0) containing 0.025% Tween 20 for antigen retrieval. The sections were incubated with hydrogen peroxide (0.3% v/v) in methanol for 30 min to quench the endogenous peroxidase activity, followed by blocking with 1% bovine serum albumin to preclude non-specific binding. Thereafter, the slides were incubated with rabbit polyclonal DPP III antibody (1 : 200 dilution) or goat polyclonal IL-6 antibody (1 : 100) for 16 h at 4 °C. The primary antibody was detected using the streptavidin–biotin complex using the Dako LSAB plus kit (Dako Cytomation, Glostrup, Denmark) and diaminobenzidine as the chromogen. All procedures were carried out at room temperature unless otherwise specified. Slides were washed with Tris-buffered saline (0.1 m, pH 7.4) three times after every step. Finally, the sections were counterstained with Mayer's hematoxylin and mounted with DPX Mountant. Tissue sections incubated with isotype-specific non-immune mouse IgG in place of primary antibody served as negative control. The immunostained sections were evaluated by light microscopy examination.
Evaluation of immunohistochemical staining
Each slide was evaluated for DPP III and IL-6 immunostaining using a scoring system for both staining intensity and the percentage of positive epithelial cells. Immunostaining was evaluated in five randomly selected areas of the tissue section. For DPP III and IL-6 protein expression, sections were scored as positive cells exhibiting cytoplasmic expression when observed independently by the senior pathologist (MCS), who was blinded to the grading of the tissue samples. The tissue sections were scored based on the percentage of DPP III and IL-6 immunopositive cells as 0–24%, 0; 25–49%, l; 50–74%, 2; and 75–100%, 3. Sections were also scored on the basis of staining intensity as negative = 0; mild = 1; moderate = 2; and intense = 3. Finally, a total score was obtained by adding the score of percentage positivity and intensity.
Constructions of DPP III promoter reporter construct and site directed mutagenesis of the C/EBP-β binding motif
In the present study we used three promoter reporter constructs (pAAS-1, pAAS-2 and pAAS-3) described by Shukla et al.  without any modification and generated a new deletion construct (pRS-1) by using the same PCR based strategy. The nucleotide sequences of the PCR primers (DPP III-494F and DPP III-NR) used for making this construct are shown in Table 1.
The mutagenesis of the C/EBP-β binding motif was essentially carried out by the PCR based strategy described by Rodriguez et al. . The C/EBP-β binding motifs at −487 and −478 5′ GCTTTGCAAC 3′ of the DPP III promoter were mutated to 5′ GCccTGCAAC 3′. The mutated bases are in lower case. The nucleotide sequences of primers used for mutagenesis are given in Table 1. Mutagenesis of the desired nucleotides in the resulting construct was confirmed by double-stranded DNA sequencing.
Transfection and luciferase assay
U87MG cells were seeded in a six-well plate (1.5 × 106 cells per well). The next day they were transfected with 1 μg of control or test plasmid DNA. After 48 h, transfected cells were processed for preparation of cell lysates and measurement of luciferase activity in the cell lysates. The details of transfection and luciferase assay have been described earlier .
For transfection of siRNA expression constructs, 4 × 106 U87MG cells were plated in a T25 flask. The next day the cells were transfected with 5 μg of control or test plasmid DNA FuGENE® HD Transfection Reagent (Promega, Madison, WI, USA), according to the manufacturer's protocol.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed with CEBP-β antibody using Imprint™ Chromatin Immunoprecipitation Kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer's protocol as described by Mir and Chauhan with the only variation that U87MG cells in place of HepG2 cells were used in the present study .
75–85% confluent cells were harvested, washed twice with ice-cold NaCl/Pi and lysed in RIPA buffer (Abcam) with 1 μg·mL−1 protease inhibitor cocktail (Sigma-Aldrich) for 10 min followed by centrifugation at 10 000 g for 10 min at 4 °C to remove debris. Supernatant cell lysates containing 50 μg of total protein were subjected to SDS/PAGE followed by western blotting as described earlier .
Treatment of U87MG cells with recombinant IL-6
1.25 × 105 U87MG cells were plated in each well of a six-well plate. The next day, the appropriate volume of recombinant IL-6 stock (eBioscience, San Diego, CA, USA) in NaCl/Pi was added to each well to achieve a final concentration of 100 nm. Cells treated with an equal volume of NaCl/Pi served as controls. After 24 h the cells were washed twice with ice-cold NaCl/Pi and processed for preparation of cell lysates.
To study the effect of IL-6 on DPP III promoter activity U87MG cells transfected with the desired promoter reporter constructs were treated with IL-6 or NaCl/Pi 24 h post transfection and processed for luciferase assays after 48 h, i.e. after 24 h of IL-6 treatment.
Construction of C/EBP-β siRNA expression vector
Three human C/EBP-β siRNA expression vectors, namely sh259, sh269 and sh1417, along with a scrambled siRNA expression vector (shSc) were constructed in the laboratory. The strategy for predicting the siRNA sequence against the target mRNA and construction of these vectors have been described earlier . The oligonucleotides used for this purpose are listed in Table 1. Silencing efficiencies of the vectors were assessed after their transient transfection in U87MG cells by western blotting.
DPP III mRNA was quantitated by real-time PCR as described by Shukla et al.  using Maxima® SYBR Green/ROX qPCR Master Mix (MBI Fermentas, Vilnius, Lithuania) and ABI Prism 7000 (Applied Biosystems, Foster City, CA, USA) thermal cycler. The primers used for this purpose are described in Table 1.
In this study statistical analysis was done using the spss 17.0 software (SPSS, Chicago, IL, USA). Spearman's correlation analysis was applied for correlating two variables of the immunohistochemical data. For comparison the paired two-tailed Student's t test for parametric data and the Mann–Whitney U test for non-parametric data were applied. P ≤0.05 was considered statistically significant.
We are grateful to Dr Riyaz A. Mir for helpful discussions while performing the ChIP assays and site directed mutagenesis. This study was supported by research grant BT/PR7146/MED/30/900/2012 from the Department of Biotechnology, Government of India, New Delhi, to SSC.